Sleep Pharmaceuticals

advair-diskus-generic
Sleep Pharmaceuticals

Generic Advair Diskus Gets Greenlight from FDA

The FDA has approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). Mylan obtained approval to […]

couple in bed man snoring
Sleep Pharmaceuticals Product & Vendor Updates

Cook Medical to Market Min-Inv Treatment for Snoring

Cook Medical and Zelegent, Inc. announced an agreement to enhance treatment options for patients suffering from snoring. Working together, the two companies will market Zelegent’s new minimally invasive technology for snoring. The Elevo® Kit Snoring Intervention Device allows physicians to perform Elevoplasty® in an office-based setting with no general anesthesia. Headquartered in […]

Sleep Pharmaceuticals Narcolepsy

Promising Data for First New Narcolepsy Drug in Ten Years, Pending Approval

Platform presentation highlights open-label, long-term safety and tolerability results, durability of effect over time in both EDS and cataplexy in patients with narcolepsy Harmony Biosciences, LLC (Harmony) recently presented new data on pitolisant at the 7th International Symposium on Narcolepsy in Beverly, MA. Pitolisant is an investigational product that has […]

lonhala magnair
Sleep Pharmaceuticals

Sunovion First To Offer Nebulized Long-Acting Muscarinic Antagonist (LAMA) For COPD In The U.S.

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution (25 mcg twice daily) is now available at pharmacies in the U.S. for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. LONHALA MAGNAIR is the first […]

sunovion LM_NebulizerSystem
Sleep Pharmaceuticals Product & Vendor Updates

Sunovion Receives FDA Approval for Lonhala™ Magnair™ Inhalation Solution to Treat COPD

Sunovion Pharmaceuticals Inc. today announced that the FDA approved the New Drug Application (NDA) for Lonhala™ Magnair™ (glycopyrrolate) Inhalation Solution (25 mcg twice daily), also known as SUN-101/eFlow®, for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Sunovion […]